Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
Stampfer SD, Goldwater MS, Jew S, Bujarski S, Regidor B, Daniely D, Chen H, Xu N, Li M, Green T, Fung E, Aquino E, Swift R, Eshaghian S, Preugschat K, Feinstein AJ, Spektor TM, Berenson JR. Stampfer SD, et al. Among authors: xu n. Leukemia. 2021 Dec;35(12):3534-3541. doi: 10.1038/s41375-021-01354-7. Epub 2021 Jul 29. Leukemia. 2021. PMID: 34326466 Free PMC article.
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, Hekmati T, Ghermezi M, Zhou M, Wang EY, Tanenbaum EJ, Zahab B, Schlossberg R, Yashar MA, Wang CS, Tang GY, Spektor TM, Berenson JR. Chen H, et al. Among authors: xu n. Leuk Res. 2019 Jun;81:62-66. doi: 10.1016/j.leukres.2019.04.008. Epub 2019 Apr 18. Leuk Res. 2019. PMID: 31035033
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, Cao J, Hekmati T, Zahab B, Nosrati JD, Wen M, Wang CS, Tang G, Xu N, Spektor TM, Berenson JR. Chen H, et al. Among authors: xu n. Br J Haematol. 2020 Jan;188(2):283-294. doi: 10.1111/bjh.16158. Epub 2019 Aug 18. Br J Haematol. 2020. PMID: 31423579 Free article.
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
Chen H, Li M, Ng N, Yu E, Bujarski S, Yin Z, Wen M, Hekmati T, Field D, Wang J, Nassir I, Yu J, Huang J, Daniely D, Wang CS, Xu N, Spektor TM, Berenson JR. Chen H, et al. Among authors: xu n. Br J Haematol. 2021 Feb;192(3):568-576. doi: 10.1111/bjh.17282. Epub 2020 Dec 20. Br J Haematol. 2021. PMID: 33341940 Free article.
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, Li M, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Regidor B, Sutanto C, Berenson JR. Bujarski S, et al. Among authors: xu n. Target Oncol. 2021 Jul;16(4):503-515. doi: 10.1007/s11523-021-00821-6. Epub 2021 Jun 7. Target Oncol. 2021. PMID: 34097243
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma.
Goldwater MS, Stampfer SD, Sean Regidor B, Bujarski S, Jew S, Chen H, Xu N, Kim C, Kim S, Berenson JR. Goldwater MS, et al. Among authors: xu n. Clin Infect Pract. 2023 Jan;17:100214. doi: 10.1016/j.clinpr.2022.100214. Epub 2022 Dec 13. Clin Infect Pract. 2023. PMID: 36530752 Free PMC article.
5,514 results